Realm Therapeutics PLC Result of AGM (2816H)

TIDMRLM

RNS Number : 2816H

Realm Therapeutics PLC

06 June 2017

Realm Therapeutics plc

("Realm Therapeutics" or the "Company")

Result of 2017 Annual General Meeting

6 June 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at www.realmtx.com.

Enquiries:

 
                                         +44 (0) 20 3727 
 Realm Therapeutics plc                   1000 
 Alex Martin, Chief Executive Officer 
  Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         +44 (0) 20 3727 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser &         +44 (0) 20 7496 
  Broker)                                 3000 
 Aubrey Powell / Lauren Kettle

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGUNRRRBSANRAR

(END) Dow Jones Newswires

June 06, 2017 06:05 ET (10:05 GMT)

Realm Thera. (LSE:RLM)
Historical Stock Chart
From Mar 2024 to Apr 2024